US OptionsDetailed Quotes
ADCT240517C2500
- 1.25
- -0.50-28.57%
15min DelayClose May 17 15:59 ET
1.25High1.25Low
1.25Open1.75Pre Close1 Volume0 Open Interest2.50Strike Price125.00Turnover0.00%IV23.78%PremiumMay 17, 2024Expiry Date1.60Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.59Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ADC Therapeutics Stock Discussion
Sign in to post a comment
$ADC Therapeutics(ADCT.US$ ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
3
$ADC Therapeutics(ADCT.US$
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
1
$ADC Therapeutics(ADCT.US$ ey yo whats going on tf
$ADC Therapeutics(ADCT.US$ will this come back up?
$ADC Therapeutics(ADCT.US$ oh wow knife
$ADC Therapeutics(ADCT.US$ ADC Therapeutics Announces Initial Data From Investigator-Initiated Phase 2 Clinical Trial of Zynlonta® in Patients With Relapsed/Refractory Marginal Zone Lymphoma ADC Therapeutics SA - Zynlonta Was Generally Well-Tolerated and Safety Was Consistent With Known Profile
1
$ADC Therapeutics(ADCT.US$ ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...
ADC Therapeutics' low P/S ratio may be due to poor growth and declining revenue. The company's underwhelming revenue outlook and shareholders' pessimism on revenue prospects contribute to the low P/S. The share price is unlikely to rise strongly soon.
No comment yet
ECsnap : What platform is this?
TrytosaveabitOP ECsnap: WB!
Jaguar8 : Grrr sometimes late
TrytosaveabitOP Jaguar8: Grrr! BENF also! Why??? Hehehe
Jaguar8 TrytosaveabitOP: Please don’t remind me it will make me cry
View more comments...